TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05687045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula
Description: High Flow Nasal Cannula will be set at 60 liters per minute of air/oxygen admixture to reach a peripheral oxygen saturation equal or greater than 94%

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Oxygen Therapy
Description: Conventional Oxygen Therapy will be administered through nasal cannula with a oxygen flow set to achieve a peripheral oxygen saturation equal or greater than 94%
Study: NCT06181162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social and/or physical environmental interventions
Description: To be determined in the co-creation groups on the four sites (Denmark, the Netherlands, Nigeria, South Africa)
Study: NCT04827862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: pembrolizumab plus low-dose (4 Gy x 5) involved-site radiotherapy
Study: NCT05876065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC
Description: Capecitabine (bid po, d1-14) and cyclophosphamide (qd po, d1-d14) every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPC
Description: Any physician's choice as maintenance therapy (except for XC regimen)
Study: NCT05686733

Intervention type: DEVICE
Group type: OTHER
Intervention: SEAL Device
Description: Endovascular treatment of target aneurysm using the Saccular Endovascular Aneurysm Lattice (SEAL) device.
Study: NCT05065463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8233
Description: Participants will receive a single subcutaneous (SC) dose of AZD8233 into the region of the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8233
Description: Participants will receive a single subcutaneous (SC) dose of AZD8233 into the region of the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8233
Description: Participants will receive a single subcutaneous (SC) dose of AZD8233 into the region of the abdomen.
Study: NCT05028101

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed autologous breast reconstruction
Description: SOC: Delayed autologous breast reconstruction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed autologous breast reconstruction
Description: SOC: Delayed autologous breast reconstruction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perioperative Functional Medicine (FM) Care
Description: SOC plus FM: A food plan that encourages consumption of nutrient-dense whole foods. It provides adequate protein, balanced quality fats and foods which contain targeted nutrients essential to proper wound healing. Select dietary supplements will be provided as an adjunct to the food plan. Health coaching will support optimal sleep, adequate movement/exercise and stress reduction.
Study: NCT05423756

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 1: Routine Care
Description: Routine Antibiotic Stewardship Arm - Continuation of antibiotic stewardship activities in accordance with national standards.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2: INSPIRE Stewardship Bundle for Skin and Soft Tissue Infection
Description: Quality improvement intervention that includes (1) computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimates for having a skin/soft tissue infection due to a multidrug-resistant organism (MDRO) and recommends standard spectrum antibiotics for low risk patients in the first 3 days of hospitalization; (2) clinician feedback reports, and (3) activities to support CPOE adoption (including education and alignment of CPOE workflows). Other antibiotic stewardship activities to continue in accordance with national standards.
Study: NCT05030090

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional consultant
Description: The control group is to be consulted by the dietitian using communication software (Line) or telephone to evaluate the nutritional requirement and guide the cancer diet principles before starting the project.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional consultant
Description: The control group is to be consulted by the dietitian using communication software (Line) or telephone to evaluate the nutritional requirement and guide the cancer diet principles before starting the project.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional consultant
Description: The control group is to be consulted by the dietitian using communication software (Line) or telephone to evaluate the nutritional requirement and guide the cancer diet principles before starting the project.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional consultant + High-calorie, high-protein liquid nutrition supplement
Description: At the beginning of the plan, the dietitian first calculates the patient's daily calorie intake and the ratio of the three macronutrients and guides the patients or their family members of the nutritional care plan group A to implement a daily diet with a concentrated high-calorie and high-protein liquid supplement (Commercial formula contains 425 kcal and 19.1 grams of protein).
Study: NCT05532319

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: HAIC sequential TAE combined with lenvatinib and tislelizumab
Description: Patients with unresectable hepatocellular carcinoma will receive hepatic arterial infusion chemotherapy (HAIC) sequential transarterial embolization combined with lenvatinib and tislelizumab.
Study: NCT05347524

Intervention type: OTHER
Intervention: Baseline blood draw and blood-based biomarkers analyses
Description: Baseline blood draw and blood-based biomarkers analyses

Intervention type: OTHER
Intervention: Baseline blood draw and blood-based biomarkers analyses
Description: Baseline blood draw and blood-based biomarkers analyses
Study: NCT04825210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Behavioral Health - Prevention
Description: IBH-P consists of 15-30 minute visits with mothers as part of the 1, 2, 4, and 6 month well-child visits. The intervention is delivered by doctoral level pediatric psychologists that are an integrated member of the primary care team.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents, 4th Edition
Description: Bright Futures curriculum will be delivered by the pediatrician as part of the 1, 2, 4 and 6 month well-child visits.
Study: NCT05030090

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nutritional consultant + Liquid supplement + Powdered supplement 1 and 2
Description: At the beginning of the plan, the dietitian first calculates the patient's daily calorie intake and the ratio of the three macronutrients and guides the patients or their family members of the nutritional care plan group B to implement a daily diet with a concentrated high-calorie and high-protein liquid supplement (Commercial formula contains 425 kcal and 19.1 grams of protein). Meanwhile, nutrition care plan group B will be given powdered supplement 1 (containing β-glucan and gamma-aminobutyric acid) and nutritional products and powdered supplement 2 (contains water-soluble dietary fiber and probiotics).
Study: NCT05513261

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: High definition colonoscopy (standard colonoscopy) in Adenoma Detection Rate
Description: In the intervention of this arm the investigators will apply the standard colonoscopy without computer-aided colonoscopy (polyDeep)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PolyDeep assisted high definition colonoscopy (CAD system) in Adenoma Detection Rate
Description: In the intervention of this arm the investigators will apply polyDeep assisted high definition colonoscopy (CAD system).
Study: NCT05556070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 1
Description: : Local retailer produce vouchers ($25 value) will be distributed to the families biweekly over a 32-week period for a total of 16 vouchers. The vouchers can be redeemed for fresh produce at the grocery store that issued the vouchers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 2
Description: Boxes of fresh fruits and vegetables (F\&V), each containing approximately 50 servings of F\&V, will be assembled by Brighter Bites at school sites using donated produce and delivered to houses using DoorDash. F\&V boxes will be distributed to families every 2 weeks over 32 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 3
Description: subjects in this arm will receive the usual standard of care at the clinic for the study period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brighter Bites app
Description: Participants in Arms 1 and 2 will also receive nutrition education using the Brighter Bites app which includes recipes for a variety of meal types or produce types, all of which are searchable. Recipes include the average cost to prepare, the number of servings, and the calories for the recipe. The Brighter Bites app also includes healthy living Brighter Choices suggestions such as tips for how to store different types of foods, gardening tips, and tips to pack a healthy lunchbox. In addition to the Brighter Bites app, trained staff will facilitate virtual nutrition education for patient families.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brighter Bites app
Description: Participants in Arms 1 and 2 will also receive nutrition education using the Brighter Bites app which includes recipes for a variety of meal types or produce types, all of which are searchable. Recipes include the average cost to prepare, the number of servings, and the calories for the recipe. The Brighter Bites app also includes healthy living Brighter Choices suggestions such as tips for how to store different types of foods, gardening tips, and tips to pack a healthy lunchbox. In addition to the Brighter Bites app, trained staff will facilitate virtual nutrition education for patient families.
Study: NCT05862779

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: The placebo group will receive 4 g per day of corn oil and 40 g per day of maltodextrin.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein + Placebo
Description: The whey protein + placebo group will receive 40g per day of whey and 4g per day of corn oil.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 + Placebo
Description: The omega 3 + placebo group will receive 4 g per day of fish oil and 40 g per day of maltodextrin.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 + Whey Protein
Description: The omega 3 + whey group will receive 4g per day of fish oil and 40g per day of protein.
Study: NCT05664126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VST infusion
Description: single intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VST infusion
Description: single intravenous (IV) infusion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: Cells infusions are prepared using the ClinMACS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: Cells infusions are prepared using the ClinMACS
Study: NCT03750500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofeedback device
Description: 12-week exercise program performed through the device
Study: NCT06543836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg, d1, with a treatment cycle of 21 days, and efficacy assessment every 2 cycles.
Study: NCT05799833

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular magnetic resonance scan - 3T scanner (Siemens Vida)
Description: 4 study groups will undergo testing with 12-lead ECG, blood test, cardiac MRI, cardiopulmonary exercise testing and 24 hour holter monitor. A subgroup (N=50 anticipated) will undergo genetic testing.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular magnetic resonance scan - 3T scanner (Siemens Vida)
Description: 4 study groups will undergo testing with 12-lead ECG, blood test, cardiac MRI, cardiopulmonary exercise testing and 24 hour holter monitor. A subgroup (N=50 anticipated) will undergo genetic testing.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular magnetic resonance scan - 3T scanner (Siemens Vida)
Description: 4 study groups will undergo testing with 12-lead ECG, blood test, cardiac MRI, cardiopulmonary exercise testing and 24 hour holter monitor. A subgroup (N=50 anticipated) will undergo genetic testing.
Study: NCT03750500

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education on falls risk
Description: Education on falls risk factors and how to minimize them

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education on falls risk
Description: Education on falls risk factors and how to minimize them
Study: NCT05799833

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular magnetic resonance scan - 3T scanner (Siemens Vida)
Description: 4 study groups will undergo testing with 12-lead ECG, blood test, cardiac MRI, cardiopulmonary exercise testing and 24 hour holter monitor. A subgroup (N=50 anticipated) will undergo genetic testing.
Study: NCT03750500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication review
Description: Medication will be reviewed to reduce sedative drugs and minimize interactions

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Medication review
Description: Medication will be reviewed to reduce sedative drugs and minimize interactions

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual and auditory screening
Description: Patients will go through visual and auditory screening as part of their regular care

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Visual and auditory screening
Description: Patients will go through visual and auditory screening as part of their regular care
Study: NCT06543836

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fruquintinib or Regorafenib
Description: The treatment regimen consists of the following options:~Option 1: Fruquintinib 5mg Qd, d1-21, Q4w, and efficacy assessment every 1.5 months.~Option 2: Regorafenib 160mg Qd, d1-21, Q4w, and efficacy assessment every 1.5 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib 5mg Qd, d1-14, with a treatment cycle of 21 days, and efficacy assessment every 2 cycles.
Study: NCT06277791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab：20mg/kg, ivdrip, D1，Q3W
Study: NCT04754932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy
Description: Group-based therapy for people living with mild to moderate stage dementia, delivered by two trained facilitators.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy
Description: Group-based therapy for people living with mild to moderate stage dementia, delivered by two trained facilitators.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy
Description: Group-based therapy for people living with mild to moderate stage dementia, delivered by two trained facilitators.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy
Description: Group-based therapy for people living with mild to moderate stage dementia, delivered by two trained facilitators.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy
Description: Group-based therapy for people living with mild to moderate stage dementia, delivered by two trained facilitators.
Study: NCT04831853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nasopharyngeal swabbing procedure (self swabbing first)
Description: Patient realises the nasal swabbing himself first, then undergoes conventionnal swabbing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nasopharyngeal swabbing procedure (conventionnal swabbing first)
Description: patient undergoes conventionnal swabbing first then realises the nasal swabbing himself
Study: NCT05209867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD oil
Description: * Each participant will be provided two 30mL(Milliliters) bottles (2000mg CBD per bottle) with a syringe dropper during their initial (baseline) visit with instructions to administer the solution under the tongue (0.5 cc \~1/2 dropper) twice per day (BID) 8-12 hours apart (morning and evening) at the prescribed daily dosage (63mg/day).~* The investigators plan to collect samples from five patients over three time points: baseline (no CBD), and after one and two months of CBD-administration
Study: NCT05750212

Intervention type: DIAGNOSTIC_TEST
Intervention: Tone
Description: Tone is a binary measurement of the pelvic floor muscle on physical examination

Intervention type: DIAGNOSTIC_TEST
Intervention: Tone
Description: Tone is a binary measurement of the pelvic floor muscle on physical examination

Intervention type: DIAGNOSTIC_TEST
Intervention: Tenderness
Description: Tenderness is a binary measurement of the pelvic floor muscle on physical examination

Intervention type: DIAGNOSTIC_TEST
Intervention: Tenderness
Description: Tenderness is a binary measurement of the pelvic floor muscle on physical examination

Intervention type: DIAGNOSTIC_TEST
Intervention: Contraction
Description: Contraction is a binary measurement of the pelvic floor muscle on physical examination

Intervention type: DIAGNOSTIC_TEST
Intervention: Contraction
Description: Contraction is a binary measurement of the pelvic floor muscle on physical examination

Intervention type: DIAGNOSTIC_TEST
Intervention: Relaxation
Description: Relaxation is a binary measurement of the pelvic floor muscle on physical examination

Intervention type: DIAGNOSTIC_TEST
Intervention: Relaxation
Description: Relaxation is a binary measurement of the pelvic floor muscle on physical examination

Intervention type: DIAGNOSTIC_TEST
Intervention: Electromyography
Description: Electromyography is a measurement of the pelvic floor muscle in microvolts

Intervention type: DIAGNOSTIC_TEST
Intervention: Electromyography
Description: Electromyography is a measurement of the pelvic floor muscle in microvolts

Intervention type: DIAGNOSTIC_TEST
Intervention: Transperineal
Description: Transperineal measurements (in millimeters) of the pelvic floor muscle using an ultrasound

Intervention type: DIAGNOSTIC_TEST
Intervention: Transperineal
Description: Transperineal measurements (in millimeters) of the pelvic floor muscle using an ultrasound

Intervention type: DIAGNOSTIC_TEST
Intervention: Pressure
Description: Pressure measurements (in millimeters) of the pelvic floor muscle using an algometer

Intervention type: DIAGNOSTIC_TEST
Intervention: Pressure
Description: Pressure measurements (in millimeters) of the pelvic floor muscle using an algometer
Study: NCT05831501

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans abdominis plane block
Description: Ultrasound guided infiltration of local anaesthetic bupivacaine via 22G Quincke needle between internal oblique and trans abdominis muscle layers in abdominal wall.
Study: NCT04659954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application O'DIDE
Description: The intervention is the use of an application that aimed to favorize contact between the patient and the care team between the consultations.
Study: NCT06012396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stoke complex exercise program
Description: 1. warm-up(5min) flexibility exercise - neck, triceps brachii, biceps brachii, forearm, back, quadriceps, biceps femoris, ankle~2. main exercise(40min) aerobic exercise(20min)- use stepper, treadmill, high intensity HRR60%, RPE 11\~14 low intensity HRR30%, RPE 9\~11 repeated interval training strength and balance exercises(20min)- program1. upper(shoulder press, chest press, biceps curl), lower(hip flexion, knee extension), Core(plank exercise, sit up) program2. upper(seated back row, triceps extension), lower(hip extension, hip abduction, knee flexion, Core(superman exercise, bridge exercise) repeated ever other day program1, program2 clean-up(5min) - same as warm-up
Study: NCT05747326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral vinorelbine and capecitabine
Description: The eligible patients were enrolled to receive oral metronomic vinorelbine 40 mg on day 1, day 3, day 5 every week (Monday, Wednesday, and Friday) and capecitabine 500mg three times daily (tid) after meals every 3 weeks. Until disease progression or unacceptable toxicity occurred, or the patient refused medication, vinorelbine and capecitabine were administered continuously without drug-free periods over 21-day cycles.
Study: NCT05717296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anxiety survey
Description: surgery and anesthesia anxiety questionnaire

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: anxiety survey
Description: surgery and anesthesia anxiety questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scale of satisfaction
Description: scale of satisfaction of multimedia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimedia Information
Description: Patients randomized to the with multimedia support arm will have access to educational videos focused on the vascular surgery they are to receive.
Study: NCT05697172

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-intensity focused ultrasound
Description: 80-second stimulus with an estimated tissue ISSPA=2.26 W/cm2, with (sham) or without (verum) interposition of Sorbothane film

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Low-intensity focused ultrasound
Description: 80-second stimulus with an estimated tissue ISSPA=2.26 W/cm2, with (sham) or without (verum) interposition of Sorbothane film
Study: NCT05287035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone injection
Description: Dexamethasone will be injected at the dosage recommended by the FDA.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: Saline will be injected for the placebo arm of the study.
Study: NCT06273319

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OXYGEN THERAPY
Description: 15 AND 30 LT OXYGEN TREATMENT
Study: NCT05734118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perfusion assessment by means of the SPY-PHI camera
Description: Minutes after injection of ICG, the intestinal perfusion can and will be assessed using the SPY-PHI camera by Stryker Endoscopy. The operative plan will not be changed based on the results of the perfusion assessment. Images will be recorded and evaluated postoperatively.